Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group Plc LSE:VEC London Ordinary Share GB00BKM2MW97 ORD 0.0271P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.20 -0.23% 85.40 85.80 86.40 87.80 85.90 87.80 240,684 16:35:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 160.5 -104.8 -13.2 - 569

Vectura Group plc Results of General Meeting

10/10/2019 1:17pm

UK Regulatory (RNS & others)


Vectura (LSE:VEC)
Historical Stock Chart

2 Months : From Sep 2019 to Nov 2019

Click Here for more Vectura Charts.

TIDMVEC

RNS Number : 5145P

Vectura Group plc

10 October 2019

Results of General Meeting

Results of the General Meeting held on 10 October 2019 at the offices of Clifford Chance LLP, 4 Coleman Street, London EC2R 5JJ.

Chippenham, UK - 10 October 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Company") announces that all resolutions proposed to shareholders at its General Meeting (GM) held today were duly passed on a poll, the results of which are set out below:

 
 Resolution           No. of votes              %      No. of          %      No. of             %      No. of 
                       for & discretionary              votes                  total votes               votes 
                                                        against                cast                      withheld 
 To declare 
  a Special 
  Dividend 
  of 6 pence 
  per ordinary 
  share in 
  the capital 
  of the Company        506,185,673            99.93     370,136       0.07     506,555,809     75.99     6,605 
                     ---------------------  --------  ------------  -------  --------------  --------  ---------- 
 To approve 
  the share 
  consolidation 
  as set out 
  in the Circular       505,701,857            99.83     836,694       0.17     506,538,551     75.99     23,863 
                     ---------------------  --------  ------------  -------  --------------  --------  ---------- 
 To authorise 
  market purchases 
  of the Company's 
  own shares*           501,388,488            99.05     4,822,433     0.95     506,210,921     75.94     351,493 
                     ---------------------  --------  ------------  -------  --------------  --------  ---------- 
 

* Passed as a special resolution.

Votes 'withheld' have not been included in the calculation of whether a resolution is carried.

A copy of the resolutions as well as the above results will shortly be available on the Company's website at https://www.vectura.com/investors/stock-exchange-announcements.

A copy of the resolutions will be submitted to the National Storage Mechanism and in due course will be available to view at http://www.morningstar.co.uk/uk/NSM using Vectura Group PLC's code 'VEC'.

As at the close of business on 10 October 2019, the issued share capital was 666,581,058 ordinary shares of GBP0.00025 each, carrying one vote each. At 10 October 2019 the Company did not hold any shares in treasury. Therefore, the total number of voting rights in the Company as at 10 October 2019 was 666,581,058.

- Ends-

For more information, please contact:

Vectura Group plc

   Elizabeth Knowles - VP Investor Relations                          +44 (0)7767 160 565 
   David Ginivan - VP Corporate Communications                 +44 (0)7471 352 720 
   Consilium Strategic Communications                                 +44 (0)20 3709 5700 

Mary-Jane Elliott / Sue Stuart / David Daley

About Vectura

Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ROMFFMFESFUSEFS

(END) Dow Jones Newswires

October 10, 2019 08:17 ET (12:17 GMT)

1 Year Vectura Chart

1 Year Vectura Chart

1 Month Vectura Chart

1 Month Vectura Chart
Your Recent History
LSE
VEC
Vectura
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191114 04:13:21